IEX •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization4,501.74 mln
Float30.01 mln
Earnings Date11/18/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
164
Transformational upside
Relative Strength
72
/ 100
Outperforming
Debt / Equity
-59.02
Negative equity
ROE
-374
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Celcuity is a Minneapolis-based clinical-stage biotechnology company founded in 2011, focused on developing new treatments for solid tumor cancers. Its primary drug candidate, Gedatolisib, is designed to block a set of proteins that drive the growth of certain advanced breast and prostate cancers. The company holds a licensing agreement with Pfizer to develop and bring Gedatolisib to market.
